GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.

Medical experts reveal alarming risks as patients seek 'quick fix' weight loss injections without meeting clinical criteria, ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

GLP-1 meds may help — or harm — those with bipolar disorder. Read firsthand accounts of mood changes, weight loss, and side ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Obesity — like most other medical conditions — requires an “arsenal” of treatments, rather than a one-size-fits-all approach.